NeoProteomics licenses biomarker technology from Case Western

MedCity News tells us about bioinformatics company NeoProteomics and its exclusive option agreement to license biomarker technology from Case Western Reserve University. The company had spun off from the university based on technology developed by Mark Chance, director of the Case Center for Proteomics and Bioinformatics.

NeoProteomics wants to use its biomarkers in potential treatments for a number of conditions, including cancer, diabetes and inflammatory diseases. The new license option covers various tools and biomarkers.

"The hard part has been picking the right [biomarkers] that look like they might have commercial potential," Chance said in a 2009 interview. "A lot of projects we do have tremendous basic science potential...but most of them are too far away from commercialization."

- read more on MedCity News

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.